Administration of exogenous Cyr61 accelerated mucosal restitution from colitis in both wild type and Cyr61 mutant mice, underscoring a therapeutic potential for Cyr61 in inflammatory bowel disease (IBD) [22]. This evidence concerns the gene CCN1 and colitis.